Multi-omic approaches to improve outcome for T-cell acute lymphoblastic leukemia patients

Publication date: Available online 26 August 2019Source: Advances in Biological RegulationAuthor(s): Jordy C.G. van der Zwet, Valentina Cordo, Kirsten Canté-Barrett, Jules P.P. MeijerinkAbstractIn the last decade, tremendous progress in curative treatment has been made for T-ALL patients using high-intensive, risk-adapted multi-agent chemotherapy. Further treatment intensification to improve the cure rate is not feasible as it will increase the number of toxic deaths. Hence, about 20% of pediatric patients relapse and often die due to acquired therapy resistance. Personalized medicine is of utmost importance to further increase cure rates and is achieved by targeting specific initiation, maintenance or resistance mechanisms of the disease. Genomic sequencing has revealed mutations that characterize genetic subtypes of many cancers including T-ALL. However, leukemia may have various activated pathways that are not accompanied by the presence of mutations. Therefore, screening for mutations alone is not sufficient to identify all molecular targets and leukemic dependencies for therapeutic inhibition. We review the extent of the driving type A and the secondary type B genomic mutations in pediatric T-ALL that may be targeted by specific inhibitors. Additionally, we review the need for additional screening methods on the transcriptional and protein levels. An integrated ‘multi-omic’ screening will identify potential targets and biomarkers to establish significant progress in...
Source: Advances in Biological Regulation - Category: Biology Source Type: research